Performance of commercial methods for linezolid susceptibility testing of Enterococcus faecium and Enterococcus faecalis.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 11 02 2020
revised: 03 04 2020
accepted: 09 04 2020
pubmed: 26 5 2020
medline: 25 6 2021
entrez: 26 5 2020
Statut: ppublish

Résumé

Linezolid-resistant enterococci (LRE) causing infections that are challenging to treat are rising, highlighting the need for reliable screening of LRE clinical isolates. To evaluate the ability of the broth microdilution (BMD) method for LRE detection and to assess the performance of seven commercially available techniques for linezolid susceptibility testing. A collection of 100 clinical isolates (80 Enterococcus faecium and 20 Enterococcus faecalis), including 20 optrA-positive isolates, 17 poxtA-positive isolates and 1 optrA/poxtA-positive E. faecium isolate, were studied. MICs were determined after 18 h [Day 1 (D1)] and 42 h [Day 2 (D2)] of incubation and interpreted following EUCAST and CLSI guidelines, which currently provide different interpretative breakpoints. Performance of commercial techniques was compared with BMD results. MIC50/D1 and MIC50/D2 were both 8 mg/L, while MIC90/D1 and MIC90/D2 were 16 and 32 mg/L, respectively. MICD1 values for poxtA-positive isolates were lower than those for optrA-positive isolates. Proportions of susceptible isolates at D1 and D2 were 48% and 41%, respectively, according to EUCAST breakpoints and 35% and 13%, respectively, according to CLSI criteria (the proportions of isolates categorized as intermediate following CLSI recommendations were 13% and 28% at D1 and D2, respectively). Percentage susceptibility assessed by the commercially available techniques was always higher. The four commercial methods allowing MIC determination provided an overall essential agreement of ≥90% at D1. Categorical agreement and error rates were generally improved at D2. Non-automated methods (Sensititre and UMIC) and, to a lesser extent, gradient strip Etest appear to show an acceptable correlation with the BMD reference method for the detection of isolates with low MICs of linezolid after prolonged incubation.

Sections du résumé

BACKGROUND
Linezolid-resistant enterococci (LRE) causing infections that are challenging to treat are rising, highlighting the need for reliable screening of LRE clinical isolates.
OBJECTIVES
To evaluate the ability of the broth microdilution (BMD) method for LRE detection and to assess the performance of seven commercially available techniques for linezolid susceptibility testing.
METHODS
A collection of 100 clinical isolates (80 Enterococcus faecium and 20 Enterococcus faecalis), including 20 optrA-positive isolates, 17 poxtA-positive isolates and 1 optrA/poxtA-positive E. faecium isolate, were studied. MICs were determined after 18 h [Day 1 (D1)] and 42 h [Day 2 (D2)] of incubation and interpreted following EUCAST and CLSI guidelines, which currently provide different interpretative breakpoints. Performance of commercial techniques was compared with BMD results.
RESULTS
MIC50/D1 and MIC50/D2 were both 8 mg/L, while MIC90/D1 and MIC90/D2 were 16 and 32 mg/L, respectively. MICD1 values for poxtA-positive isolates were lower than those for optrA-positive isolates. Proportions of susceptible isolates at D1 and D2 were 48% and 41%, respectively, according to EUCAST breakpoints and 35% and 13%, respectively, according to CLSI criteria (the proportions of isolates categorized as intermediate following CLSI recommendations were 13% and 28% at D1 and D2, respectively). Percentage susceptibility assessed by the commercially available techniques was always higher. The four commercial methods allowing MIC determination provided an overall essential agreement of ≥90% at D1. Categorical agreement and error rates were generally improved at D2.
CONCLUSIONS
Non-automated methods (Sensititre and UMIC) and, to a lesser extent, gradient strip Etest appear to show an acceptable correlation with the BMD reference method for the detection of isolates with low MICs of linezolid after prolonged incubation.

Identifiants

pubmed: 32449911
pii: 5843866
doi: 10.1093/jac/dkaa180
doi:

Substances chimiques

Anti-Bacterial Agents 0
Linezolid ISQ9I6J12J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2587-2593

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Loren Dejoies (L)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
U1230 'ARN régulateurs Bactériens et Médecine', Université Rennes 1, Rennes, France.

Sarrah Boukthir (S)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.

Gauthier Péan de Ponfilly (G)

Hôpital Lariboisière, Service de Bactériologie-Virologie, Paris, France.

Ronan Le Guen (R)

Hôpitaux Universitaires Henri Mondor, Unité de Bactériologie-Hygiène, Créteil, France.

Asma Zouari (A)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

Sophie Potrel (S)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

Anaïs Collet (A)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

Gabriel Auger (G)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

Hervé Jacquier (H)

Hôpital Lariboisière, Service de Bactériologie-Virologie, Paris, France.

Vincent Fihman (V)

Hôpitaux Universitaires Henri Mondor, Unité de Bactériologie-Hygiène, Créteil, France.
EA 7380 Dynamyc, EnvA, UPEC, Paris-Est University, Créteil, France.

Laurent Dortet (L)

CHU de Bicêtre, service de Bactériologie-Hygiène, Le Kremlin-Bicêtre, France.

Vincent Cattoir (V)

CHU de Rennes, Service de Bactériologie et Hygiène Hospitalière, Rennes, France.
U1230 'ARN régulateurs Bactériens et Médecine', Université Rennes 1, Rennes, France.
CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH